

## ***MolMed: Publication of the half-year Financial report as of 30 June 2019 (in Italian).***

Milan (Italy), August 1<sup>st</sup> 2019 – MolMed S.p.A. (MLMD.MI), biotechnology company focused on research, development, production and clinical validation of gene and cell therapies for the treatment of cancer and rare diseases, informs that the half-year Financial report as of 30 June 2019 is available to the public in Italian on the Company website ([www.molmed.com](http://www.molmed.com)) into the section Investors/Financial Reports and on the authorized centralized storage device 1Info-Storage ([www.1info.it](http://www.1info.it)).

### ***About MolMed***

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed is the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies ex vivo for its proprietary products (Zalmoxis™) as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies.

MolMed's product portfolio includes proprietary anti-tumor therapies in both clinical and preclinical development: Zalmoxis™ (TK), is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Still focusing on this cell & gene technology, the Company is developing a new therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic; the most advanced product, CAR-T CD44v6, which in March 2019 received the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase. The product, whose innovative spacer incorporated in the CAR protein received in May 2019 the confirmation of grant, is potentially effective also in several epithelial solid tumors. MolMed is also developing a pipeline based on NK (Natural Killer) cells, following a research agreement signed in 2018 with Glycostem. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

### ***For further information:***

#### ***Ilaria Candotti***

***Investor Relations & Communication Manager***

MolMed S.p.A.

+39 02 21277.205

[investor.relations@molmed.com](mailto:investor.relations@molmed.com)

#### ***Tommasina Cazzato***

***Press Office***

Community Group

+39 345 7357751

[tommasina.cazzato@communitygroup.it](mailto:tommasina.cazzato@communitygroup.it)